US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
SNDK
$1,704.16
▼-0.92%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Indivior Pharmaceuticals, Inc. - Common Stock
(NQ:
INDV
)
35.99
+0.28 (+0.78%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Indivior Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders
September 30, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
September 17, 2026
Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Halper Sadeh LLC is Investigating Whether INDV, FHB, BGMS are Obtaining Fair Deals for their Shareholders
September 08, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
August 29, 2026
From
Halper Sadeh LLC
Via
Business Wire
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score
↗
July 17, 2026
Via
Chartmill
Indivior Pharmaceuticals (NASDAQ:INDV) Passes Minervini Trend Template and High Growth Momentum Screen
↗
June 02, 2026
Via
Chartmill
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Smashes Q1 Estimates and Lifts Full-Year Outlook as SUBLOCADE Sales Surge
↗
April 30, 2026
Via
Chartmill
Indivior Q2 2026 Earnings Call: Complete Transcript
↗
August 17, 2026
Indivior (NASDAQ:INDV) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For...
Via
Benzinga
Topics
Earnings
Why Supernus Pharmaceuticals Stock Topped the Market Today
↗
August 03, 2026
It's effecting a "merger of equals" with a peer.
Via
The Motley Fool
Halper Sadeh LLC is Investigating Whether LNTH, ATKR, INDV are Obtaining Fair Deals for their Shareholders
August 03, 2026
From
Halper Sadeh LLC
Via
GlobeNewswire
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
August 03, 2026
From
Halper Sadeh LLC
Via
Business Wire
Indivior Pharmaceuticals Inc (NASDAQ:INDV) Shows High Growth Momentum and Technical Breakout Potential
↗
April 21, 2026
Via
Chartmill
Indivior Q2 Earnings Call Highlights
↗
August 03, 2026
Supernus Pharmaceuticals and Indivior (NASDAQ:INDV) announced plans to combine in an all-stock, tax-free merger of equals that the companies said would create a central nervous system-focused...
Via
MarketBeat
Topics
Earnings
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
August 03, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
August 03, 2026
From
Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
Via
GlobeNewswire
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
July 23, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
↗
June 14, 2026
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
What to Know About This Fund's $74.8 Million Indivior Sale
↗
May 30, 2026
Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%
↗
May 30, 2026
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
What to Know About This Fund's $61.5 Million Exit From Ecovyst Amid a 75% Stock Rally
↗
May 29, 2026
Ecovyst delivers catalysts and sulfuric acid services to global refining and chemical industries with advanced process solutions.
Via
The Motley Fool
Topics
Regulatory Compliance
Supply Chain
New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
May 20, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Indivior to Participate in Upcoming Investor Conferences
May 14, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally
↗
May 11, 2026
Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets.
Via
The Motley Fool
Topics
Regulatory Compliance
Indivior Announces $175 Million Accelerated Share Repurchase
May 04, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Indivior (INDV) Q1 2026 Earnings Transcript
↗
May 01, 2026
Indivior (INDV) Q1 2026 Earnings Transcript
Via
The Motley Fool
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
April 30, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
April 24, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
April 16, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
April 09, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
March 31, 2026
From
Indivior Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
